Could taking drug holidays improve CLL treatment?
NCT ID NCT07014917
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether taking the targeted drug venetoclax on an intermittent schedule (with breaks) works as well as taking it continuously, when combined with acalabrutinib, in people with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. About 62 participants will be randomly assigned to one of the two schedules. The goal is to see if the intermittent approach can achieve similar remission rates while possibly reducing side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
University of Cincinnati
RECRUITINGCincinnati, Ohio, 45219, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Can a Three-Drug combo outsmart High-Risk CLL?
- Can a gentler dose of zanubrutinib keep CLL at bay in the very elderly?
- Can a Two-Drug combo wipe out hidden leukemia cells?
- Can a Chemo-Free pill combo outsmart leukemia at first diagnosis?